ReviewFrontiers in oncology2021
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy.Molecular therapy. Oncology · 2026Article
- IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.Nature communications · 2026Article
- SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment.Neoplasia (New York, N.Y.) · 2026Article
- The immunosuppressive tumor microenvironment in glioblastoma.Frontiers in immunology · 2026Review
- Loss ofJournal of Cancer · 2026Article
- Review
- Race and "omic" data in glioma: A systematic review of contemporary research to explore the digital divide.Neuro-oncology practice · 2025Article
- RACK1 promotes NF-κB pathway activation and glioma cell proliferation by inhibiting RPS2 ubiquitination.Molecular biology reports · 2025Article
- Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche.Nature communications · 2025Article
- Unraveling Glioblastoma: TME Implication and Gene Therapy Advances.Current gene therapy · 2025Review
- Spatiotemporal Insights into Glioma Oncostream Dynamics: Unraveling Formation, Stability, and Disassembly Pathways.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Viruses in glioblastoma: an update on evidence and clinical trials.BJC reports · 2024Review
- Expressions of the satellite repeat HSAT5 and transposable elements are implicated in disease progression and survival in glioma.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- 'Slicing' glioblastoma drivers with the Swiss cheese model.Trends in cancer · 2024Review
- Advancements in Glioma Care: Focus on Emerging Neurosurgical Techniques.Biomedicines · 2023Review
- TSPO PET signal using [European journal of nuclear medicine and molecular imaging · 2023Article
- Impact of epigenetic reprogramming on antitumor immune responses in glioma.The Journal of clinical investigation · 2023Review
- Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma.Frontiers in pharmacology · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Funding
Abstract
High grade gliomas are malignant brain tumors that arise in the central nervous system, in patients of all ages. Currently, the standard of care, entailing surgery and chemo radiation, exhibits a survival rate of 14-17 months. Thus, there is an urgent need to develop new therapeutic strategies for these malignant brain tumors. Currently, immunotherapies represent an appealing approach to treat malignant gliomas, as the pre-clinical data has been encouraging. However, the translation of the discoveries from the bench to the bedside has not been as successful as with other types of cancer, and no long-lasting clinical benefits have been observed for glioma patients treated with immune-mediated therapies so far. This review aims to discuss our current knowledge about gliomas, their molecular particularities and the impact on the tumor immune microenvironment. Also, we discuss several murine models used to study these therapies pre-clinically and how the model selection can impact the outcomes of the approaches to be tested. Finally, we present different immunotherapy strategies being employed in clinical trials for glioma and the newest developments intended to harness the immune system against these incurable brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.